Tweet
I was wondering how to interpret the Kmer content graph in fastqc. I have attached it. It seems from my graph that 50% of all reads have the 6 kmers listed ? Is this a normal graph ?
-
-
Is this RNA-seq data?
Following thread may be useful (though it refers to a MiSeq run the issue is applicable to illumina sequencing in general): http://seqanswers.com/forums/showthread.php?t=30448
One more: http://seqanswers.com/forums/showthread.php?t=17219Last edited by GenoMax; 08-13-2013, 11:57 AM. -
Thank you very much, GenoMax, for the links. They are very informative.
This is RNA-Seq. It seems the first 12 or so bases are due to 'random' priming, but I was also wondering about why the lines on the graph stay up at ~50% for the length of the graph ? Random priming would explain the first 12 or so bases, but why the steady % for the rest of the sequence ?Comment
-
-
Thanks again for your help, GenoMax.
My sequence length is only 50 bases and the quality is very good.
From what I read on the linked site, it seems that I have 6 kmers that are 50-fold enriched throughout the length of my sequence. But what does this mean in terms of sample quality ?
If I have 25-30 million reads and there is a 50 fold enrichment of these kmers (most likely I would guess from the adaptor) then how many sequences does that affect ? So, if there were 100,000 sequences in which had adaptor sequence at various positions other than the end of the sequence what would the fold-enrichment be ? 100,000 affected sequences may be enough to make the fold-enrichment high, but they are only a small percentage of the total. On the other hand, if I had a much smaller number of total sequences, then the fold-enrichment may be a problem. So, I guess I want to know how to relate fold-enrichment and total number of sequences in order to tell if the fold-enrichment is a problem or just from an insignificant part of the total.Comment
-
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM -
Love this - good data definitely starts from good input, and poor input can only give relatively poor data. I particularly like the mention of Nanodrop/absorbance based methods for quantification. It's such a toss up if you'll get an accurate reading or what amounts to a randomly generated number, and a lot of library/sequencing related issues can be traced back to poor quant.07-01-2026, 11:43 AM
Comment